Clinical Trial Update: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the combination of lenalidomide with DA-EPOCH-R in MYC-associated B-cell lymphomas has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Adriamycin (doxorubicin)
• Cytoxan (cyclophosphamide)
• Oncovin (vincristine)
• PREDNISONE (Prednisone)
• Revlimid (lenalidomide)
• Rituxan (rituximab)
• Toposar (Etoposide)

Snippet

Sponsor: University of Chicago | Conditions: Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-03-11